(DBVT) DBV Technologies - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.099m USD | Total Return: 107.3% in 12m
Avg Turnover: 3.28M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Interest Coverage Ratio -261.9 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
DBV Technologies (DBVT) is a French clinical-stage biopharmaceutical firm specializing in epicutaneous immunotherapy. The company utilizes its proprietary Viaskin technology platform to deliver biologically active compounds through intact skin, avoiding direct bloodstream entry to minimize systemic allergic reactions. Its lead product candidate, Viaskin Peanut, has finished Phase 3 trials, while Viaskin Milk is currently in Phase 1/2 development for cows milk protein allergies.
The biotechnology sector often faces high R&D costs and rigorous regulatory hurdles before a product reaches commercialization. DBV’s business model relies on strategic partnerships, such as its collaboration with Nestlé Health Science, to co-develop diagnostic tools like the MAG1C atopy patch test. Beyond food allergies, the company is exploring applications for its skin-patch technology in treating celiac disease.
You may find additional financial metrics and peer comparisons on ValueRay to assist in your evaluation. DBV Technologies remains focused on securing regulatory approvals to transition from a research-heavy entity to a commercial-stage provider of allergy treatments.
- FDA regulatory clearance for Viaskin Peanut patch remains primary stock catalyst
- Clinical trial progress for Viaskin Milk determines long-term platform expansion
- Cash runway stability depends on capital raises or strategic partnerships
- Competition from oral immunotherapy treatments threatens future market share capture
- Manufacturing scalability of epicutaneous technology impacts commercial gross margins
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 122.0 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -150.6m > Net Income -167.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (85.7m) vs 12m ago -10.93% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 5.43%; Δ -5.43% > 0%) |
| Interest Coverage Ratio: -261.9 > 6 (EBITDA TTM -159.5m / Interest Expense TTM 656k) |
| A: 0.73 (Total Current Assets 246.7m - Total Current Liabilities 51.8m) / Total Assets 266.4m |
| B: -1.65 (Retained Earnings -440.7m / Total Assets 266.4m) |
| C: -1.08 (EBIT TTM -171.8m / Avg Total Assets 158.5m) |
| D: -7.12 (Book Value of Equity -416.6m / Total Liabilities 58.5m) |
| Altman-Z'' = -15.36 = D |
As of May 24, 2026, the stock is trading at USD 18.57 with a total of 167,390 shares traded.
Over the past week, the price has changed by -7.48%,
over one month by -7.43%,
over three months by -14.37% and
over the past year by +107.30%.
DBV Technologies has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold DBVT.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 40.5 | 118% |
P/B = 5.2838
Revenue TTM = 0.0 USD
EBIT TTM = -171.8m USD
EBITDA TTM = -159.5m USD
Long Term Debt = 5.10m USD (estimated: total debt 16.3m - short term 11.2m)
Short Term Debt = 11.2m USD (from shortTermDebt, last quarter)
Debt = 22.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.10m
Net Debt = -206.8m USD (calculated: Debt 22.4m - CCE 229.2m)
Enterprise Value = 892.2m USD (1.10b + Debt 22.4m - CCE 229.2m)
Interest Coverage Ratio = -261.9 (Ebit TTM -171.8m / Interest Expense TTM 656k)
EV/FCF = -5.89x (Enterprise Value 892.2m / FCF TTM -151.5m)
FCF Yield = -16.98% (FCF TTM -151.5m / Enterprise Value 892.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 17.7m) / Revenue TTM)
Tobins Q-Ratio = 3.35 (Enterprise Value 892.2m / Total Assets 266.4m)
Interest Expense / Debt = 2.93% (Interest Expense 656k / Debt 22.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -135.8m (EBIT -171.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.76 (Total Current Assets 246.7m / Total Current Liabilities 51.8m)
Debt / Equity = 0.11 (Debt 22.4m / totalStockholderEquity, last quarter 207.9m)
Debt / EBITDA = 1.30 (negative EBITDA) (Net Debt -206.8m / EBITDA -159.5m)
Debt / FCF = 1.36 (negative FCF - burning cash) (Net Debt -206.8m / FCF TTM -151.5m)
Total Stockholder Equity = 128.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -105.9% (out of range, set to none)
RoE = -29.47% (Net Income TTM -167.8m / Total Stockholder Equity 569.6m)
RoCE = -29.90% (EBIT -171.8m / Capital Employed (Equity 569.6m + L.T.Debt 5.10m))
RoIC = -60.20% (negative operating profit) (NOPAT -135.8m / Invested Capital 225.5m)
WACC = 11.71% (E(1.10b)/V(1.12b) * Re(11.90%) + D(22.4m)/V(1.12b) * Rd(2.93%) * (1-Tc(0.21)))
Discount Rate = 11.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -4.49 | Cagr: -4.97%
[DCF] Fair Price = unknown (Cash Flow -151.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.45 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=+19.59% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=-8.44% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.45 | Chg30d=+1.04% | Revisions=+0% | GrowthEPS=+51.0% | GrowthRev=-24.3%
EPS next Year (2027-12-31): EPS=-0.42 | Chg30d=-85.53% | Revisions=-33% | GrowthEPS=+6.0% | GrowthRev=+2025.4%
[Analyst] Revisions Ratio: -33%